Biomarkers for Psychiatric Drugs: Outlier or Opportunity?

A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.